77. Risk markers for sudden unexpected death in epilepsy: an observational, prospective, multicentre cohort study.
作者: Manuela Ochoa-Urrea.;Xi Luo.;Laura Vilella.;Nuria Lacuey.;Shirin Jamal Omidi.;Norma J Hupp.;Blanca Talavera.;Johnson P Hampson.;M R Sandhya Rani.;Shiqiang Tao.;Xiaojin Li.;Christina Y Miyake.;Licong Cui.;Jaison S Hampson.;Ganne Chaitanya.;Yash Shashank Vakilna.;Rup K Sainju.;Daniel Friedman.;Maromi Nei.;Luke Allen.;Catherine A Scott.;Joana Oliveira.;Brian Gehlbach.;Stephan U Schuele.;Jennifer A Ogren.;Ronald M Harper.;Beate Diehl.;Lisa M Bateman.;George B Richerson.;Jose-Miguel Yamal.;Guo-Qiang Zhang.;Orrin Devinsky.;Samden D Lhatoo.
来源: Lancet. 2025年406卷10511期1497-1507页
Sudden unexpected death in epilepsy (SUDEP) is the leading cause of epilepsy-related mortality. Generalised-particularly nocturnal-convulsive seizures, longstanding epilepsy, and solitary living have been identified retrospectively as risk factors. No definitive electroclinical biomarkers have been prospectively ascertained. This study aimed to identify SUDEP risk markers using multimodality data with long-term follow-up.
78. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.
作者: Tamara S Hannon.;Lily C Chao.;Margarita Barrientos-Pérez.;Karthik Chandrasekhar Pamidipati.;Laura Fernández Landó.;Clare J Lee.;Hiren Patel.;Brandon K Bergman.
来源: Lancet. 2025年406卷10511期1484-1496页
Current treatment options for youth-onset type 2 diabetes are limited and have demonstrated lower glycaemic efficacy than those for adult-onset type 2 diabetes. We aimed to assess the safety and efficacy of tirzepatide, a glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, compared with placebo in youth-onset type 2 diabetes.
|